Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

@article{Advani2011LongtermAO,
  title={Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.},
  author={Andrew Advani and Qingling Huang and Kerri Thai and Suzanne L. Advani and Kathryn Elizabeth White and Darren J. Kelly and Darren A. Yuen and Kim A Connelly and Philip A. Marsden and Richard E Gilbert},
  journal={The American journal of pathology},
  year={2011},
  volume={178 5},
  pages={2205-14}
}
Epigenetic changes in gene expression play a role in the development of diabetic complications, including nephropathy. Histone deacetylases (HDACs) are a group of enzymes that exert epigenetic effects by altering the acetylation status of histone and nonhistone proteins. In the current study, we investigated the action of the clinically available HDAC inhibitor vorinostat in a mouse model of diabetic nephropathy, with the following aims: to define its effect on the progression of renal injury… CONTINUE READING